(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior…
(IN BRIEF) AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer…
(IN BRIEF) Eckert & Ziegler and Ariceum Therapeutics have signed a global supply agreement for critical medical radionuclides Actinium-225 (Ac-225)…
(IN BRIEF) Boehringer Ingelheim has launched EURICAN® L4, a new vaccine designed to protect dogs from leptospirosis, a potentially fatal…
(IN BRIEF) QIAGEN is investing in a new innovation hub in Esplugues de Llobregat, Barcelona, to enhance its QIAstat-Dx syndromic…
(IN BRIEF) The European Commission has approved Theralugand®, Eckert & Ziegler's high-purity Lutetium-177 chloride, for routine clinical use across the…
(IN BRIEF) Boehringer Ingelheim has launched VETMEDIN® Solution, the first FDA-approved liquid treatment for congestive heart failure (CHF) in dogs…
(IN BRIEF) Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an adjuvant…
(IN BRIEF) Roche has announced the acquisition of Poseida Therapeutics, a clinical-stage biopharmaceutical company specializing in off-the-shelf CAR-T cell therapies,…
(IN BRIEF) Roche provided an update on its Phase III SKYSCRAPER-01 study, evaluating tiragolumab in combination with Tecentriq® for patients…